Press Releases
Company News
View Summary Medivation Enters Into License Agreement With OncoFusion for Compounds Targeting Bromodomain Proteins
Apr 23, 2014
PDF 12.7 KB Add to Briefcase
View Summary Medivation Appoints Patrick Machado to Board of Directors
Apr 17, 2014
PDF 9.4 KB Add to Briefcase
View Summary Astellas Announces European Regulatory Submission For XTANDI® (enzalutamide) Capsules For Chemotherapy-Naive Metastatic Prostate Cancer
Apr 3, 2014
PDF 56.5 KB Add to Briefcase
View Summary Medivation Names Rick Bierly Chief Financial Officer
Mar 31, 2014
PDF 9.9 KB Add to Briefcase
View Summary Astellas and Medivation Submit Supplemental New Drug Application for XTANDI (Enzalutamide) for Chemotherapy-Naive Advanced Prostate Cancer
Mar 18, 2014
PDF 56.7 KB Add to Briefcase
View Summary Medivation Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update
Feb 27, 2014
PDF 77.1 KB Add to Briefcase
View Summary Medivation Announces Fourth Quarter and Year-End 2013 Financial Results Teleconference on February 27, 2014
Feb 10, 2014
PDF 9.2 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conference
Jan 31, 2014
PDF 9.4 KB Add to Briefcase
View Summary Medivation to Host Teleconference on January 30, 2014 to Discuss Final Results From the Phase 3 PREVAIL Trial
Jan 28, 2014
PDF 9.3 KB Add to Briefcase
View Summary Medivation and Astellas Announce Final Results From the Phase 3 PREVAIL Trial of Enzalutamide in Men With Metastatic Prostate Cancer Progressing on Androgen Deprivation Therapy
Jan 28, 2014
PDF 65.7 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conference
Jan 6, 2014
PDF 9.6 KB Add to Briefcase
View Summary Data From PREVAIL Trial of Enzalutamide in Chemotherapy-Naive Metastatic Prostate Cancer to Be Presented in Late-Breaking Session at ASCO GU Symposium
Dec 19, 2013
PDF 62.0 KB Add to Briefcase
View Summary Medivation and Astellas Initiate Phase 2 Study of Enzalutamide in Advanced Breast Cancer That Is Estrogen or Progesterone Receptor Positive and HER2 Normal
Dec 4, 2013
PDF 62.0 KB Add to Briefcase
View Summary Medivation and Astellas Initiate Phase 3 Study of Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer
Dec 3, 2013
PDF 59.0 KB Add to Briefcase
View Summary Medivation Reports Third Quarter Financial Results and Provides Corporate Update
Nov 12, 2013
PDF 74.8 KB Add to Briefcase
View Summary Medivation and Astellas Initiate Trial Evaluating Benefit of Continued Enzalutamide Treatment Beyond Disease Progression in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
Nov 12, 2013
PDF 59.1 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conferences
Oct 30, 2013
PDF 9.6 KB Add to Briefcase
View Summary Medivation Announces Third Quarter 2013 Financial Results Teleconference on November 12, 2013
Oct 28, 2013
PDF 9.1 KB Add to Briefcase
View Summary Medivation and Astellas Announce the Phase 3 PREVAIL Trial of Enzalutamide Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naive Patients With Advanced Prostate Cancer
Oct 22, 2013
PDF 65.5 KB Add to Briefcase
View Summary New Survey Reveals U.S. Men with Advanced Prostate Cancer Worry More about Burdening Family and Friends Than Dying
Sep 26, 2013
PDF 819.5 KB Add to Briefcase
Showing 1-20 of 291 Page: 1 2 3 4 5 ... 15  Next 20
Add to Briefcase = add release to Briefcase

Top